Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Patrick R. Lennard"'
Publikováno v:
Antibiotics, Vol 12, Iss 10, p 1518 (2023)
Due to their ability to eliminate antimicrobial resistant (AMR) bacteria and to modulate the immune response, host defence peptides (HDPs) hold great promise for the clinical treatment of bacterial infections. Whereas monotherapy with HDPs is not lik
Externí odkaz:
https://doaj.org/article/ec6751889ac34d43b54f06de88c8bbf8
Autor:
Miriam E. van Gent, Tanny J. K. van der Reijden, Patrick R. Lennard, Adriëtte W. de Visser, Bep Schonkeren-Ravensbergen, Natasja Dolezal, Robert A. Cordfunke, Jan Wouter Drijfhout, Peter H. Nibbering
Publikováno v:
Antibiotics, Vol 11, Iss 5, p 673 (2022)
Recently, using a deep learning approach, the novel antibiotic halicin was discovered. We compared the antibacterial activities of two novel bactericidal antimicrobial agents, i.e., the synthetic antibacterial and antibiofilm peptide (SAAP)-148 with
Externí odkaz:
https://doaj.org/article/14e56718b98c40b79d1011d2b3794d33
Autor:
Alana J. De Luca, A. Bruce Lyons, Peter R. Murphy, Amanda L. Patchett, Jocelyn M. Darby, Gregory M. Woods, Andrew S. Flies, Terry L. Pinfold, Chrissie E. B. Ong, Patrick R. Lennard
Publikováno v:
Science Advances
A simple cut-and-paste reagent development method applicable to any species reveals checkpoint molecules on transmissible cancers.
Around 40% of humans and Tasmanian devils (Sarcophilus harrisii) develop cancer in their lifetime, compared to les
Around 40% of humans and Tasmanian devils (Sarcophilus harrisii) develop cancer in their lifetime, compared to les
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98d464bfc77591f11bc818ab98e2706f
http://europepmc.org/articles/PMC7458443
http://europepmc.org/articles/PMC7458443
Autor:
Gregory M. Woods, A. Bruce Lyons, Peter R. Murphy, Patrick R. Lennard, Candida Wong, Jocelyn M. Darby, Terry L. Pinfold, Andrew S. Flies
Immune checkpoint immunotherapy is a pillar of human oncology treatment with potential for non-human species. The first checkpoint immunotherapy approved for human cancers targeted the CTLA4 protein. CTLA4 can inhibit T cell activation by capturing a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::731d4ba684d3fd47372f68362b11ceef
https://doi.org/10.1101/2020.06.11.145789
https://doi.org/10.1101/2020.06.11.145789
Autor:
Peter R. Murphy, Amanda L. Patchett, Andrew S. Flies, Terry L. Pinfold, Jocelyn M. Darby, Patrick R. Lennard
Publikováno v:
Bio Protoc
This protocol provides a step-by-step method to create recombinant fluorescent fusion proteins that can be secreted from mammalian cell lines. This builds on many other recombinant protein and fluorescent protein techniques, but is among the first to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60408648c0a8633e83c7af13015c748a
https://pubmed.ncbi.nlm.nih.gov/33659348
https://pubmed.ncbi.nlm.nih.gov/33659348
Autor:
Gregory M. Woods, A. Bruce Lyons, Peter R. Murphy, Jocelyn M. Darby, Andrew S. Flies, Amanda L. Patchett, Terry L. Pinfold, Chrissie E. B. Ong, Patrick R. Lennard
Around 40% of humans and captive Tasmanian devils (Sarcophilus harrisii) develop cancer, compared to less than 10% for most species. Tasmanian devils also suffer from two of the three known naturally-occurring transmissible cancers detected in verteb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06256d85c854e94de0e93d998ae5b14
https://doi.org/10.1101/831404
https://doi.org/10.1101/831404